

Company Overview

CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing.

Our revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics.

Our mission at CollPlant is to deliver ground-breaking products for regenerative medicine that offer the optimal treatment options to patients.

3D Systems and CollPlant Enter Co-development Agreement to Deliver Bioprinted Solutions for Improved Breast Reconstruction Treatments

Jun 22 2021, 7:30 AM EDT

CollPlant Announces Effectiveness of Uplisting to the Nasdaq Global Market®; Ordinary Shares Replace ADSs

Jun 4 2021, 7:00 AM EDT

CollPlant Biotechnologies Reports First Quarter 2021 Financial Results with Record Revenues of \$14.5 Million

May 27 2021, 7:00 AM EDT

Stock Overview

Symbol	CLGN
Exchange	Nasdaq
Market Cap	182.49m
Last Price	\$17.79
52-Week Range	\$16.10 - \$23.49

Investor Relations

Eran Rotem
Deputy CEO & CFO
T: +972 (73) 2325612
F: +972 (73) 2325602
eran@collplant.com

07/30/2021 04:00 PM EDT

Management Team

Yehiel Tal

Chief Executive Officer

Prof. Oded Shoseyov

Founder, Chief Scientist

Eran Rotem, CPA

Deputy CEO and Chief Financial Officer

Dr. Nadav Orr

Vice President, Research and Development

Dr. Ilana Belzer

Chief Operating Officer

Dr. Philippe Bensimon

Vice President, Regulatory Affairs and Quality Assurance

Hadas Dreihor Horowitz

Vice President of Human Resources

CollPlant Biotechnologies Ltd.

4 Oppenheimer St.,
P.O.B 4132
Rehovot 7670104,
Israel

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.